| Laura Kristin Conrey, PA-C | |
|
3901 Central Pike Ste 352, Hermitage, TN 37076-3421 | |
| (615) 882-4000 | |
| (615) 882-4002 |
| Full Name | Laura Kristin Conrey |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 21 Years |
| Location | 3901 Central Pike Ste 352, Hermitage, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205861929 | NPI | - | NPPES |
| 11724090 | Other | TN | CAQH |
| 3663898 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | PA1092 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tristar Summit Medical Center | Hermitage, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hermitage Primary Care Llc | 3678575164 | 5 |
News Archive
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
Dr Frank McKeon, Senior Group Leader of the Stem Cell and Developmental Biology at A*STAR's Genome Institute of Singapore, and Principal Investigator Dr Wa Xian at A*STAR's Institute of Medical Biology, together with their counterparts from the Harvard Medical School, the Brigham and Women's Hospital in Boston, and the National University of Singapore, have made the striking finding that Barrett's esophagus work, published online in the journal Cell on 24 June 2011, is essential to developing therapeutics for esophageal cancer.
According to the Center for Disease Control (CDC), Taiwanese health authorities are examining a possible link between soil bacteria and the deaths of at least six people and the hospitalization of ten others in southern Taiwan.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Today's headlines include reports about the latest health policy developments on Capitol Hill and news on the health insurance marketplace.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Kristin Conrey, PA-C 3901 Central Pike Ste 352, Hermitage, TN 37076-3421 Ph: (615) 882-4000 | Laura Kristin Conrey, PA-C 3901 Central Pike Ste 352, Hermitage, TN 37076-3421 Ph: (615) 882-4000 |
News Archive
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
Dr Frank McKeon, Senior Group Leader of the Stem Cell and Developmental Biology at A*STAR's Genome Institute of Singapore, and Principal Investigator Dr Wa Xian at A*STAR's Institute of Medical Biology, together with their counterparts from the Harvard Medical School, the Brigham and Women's Hospital in Boston, and the National University of Singapore, have made the striking finding that Barrett's esophagus work, published online in the journal Cell on 24 June 2011, is essential to developing therapeutics for esophageal cancer.
According to the Center for Disease Control (CDC), Taiwanese health authorities are examining a possible link between soil bacteria and the deaths of at least six people and the hospitalization of ten others in southern Taiwan.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Today's headlines include reports about the latest health policy developments on Capitol Hill and news on the health insurance marketplace.
› Verified 7 days ago
Mr. Michael Warren, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3939 Central Pike, Hermitage, TN 37076 Phone: 615-883-2331 Fax: 615-391-1785 | |
Morgan Danae Sorrels, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 3786 Central Pike Ste 110, Hermitage, TN 37076 Phone: 615-964-5941 | |
Samantha Maye Sample, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 5653 Frist Blvd Ste 738, Hermitage, TN 37076 Phone: 615-320-0007 Fax: 615-526-6477 | |
Hannah Hertel, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 5651 Frist Blvd Ste 200, Hermitage, TN 37076 Phone: 615-885-0200 Fax: 615-885-0267 | |
Mrs. Angela Lyn Collins, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 5651 Frist Blvd, Suite 712, Hermitage, TN 37076 Phone: 615-872-9966 Fax: 615-872-9967 | |
Bailey Sloan Presley, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 5651 Frist Blvd Ste 603, Hermitage, TN 37076 Phone: 615-889-1968 Fax: 615-889-5527 | |
Shelby M Vogel, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 5653 Frist Blvd Ste 332, Hermitage, TN 37076 Phone: 615-320-0007 Fax: 615-383-6329 |